Merck

India has world-class talent, 'right momentum' for chip growth: Merck exec

Merck EVP Hans-Joachim Neumann says India's industrial base and skilled talent make it globally competitive as Merck signs pact with Tata Electronics to boost semiconductor capabilities

AI + Leadership: Lessons from Merck’s Global Head

AI meets leadership in this episode of Manager’s Mantra with Dr. Harsha Gurulingappa, Global Head of AI at Merck. Learn how tech is reshaping healthcare and what it takes to lead in the AI era.

Merck's potential cholesterol pill succeeds in late-stage studies

The company is searching for its next blockbuster candidate as its major revenue driver, Keytruda, is expected to lose patent protection by the end of the decade

Merck to invest $1 bn in new Delaware plant to boost US manufacturing

The company expects labs at the new facility to be fully operational by 2028 and produce experimental drugs by 2030

AstraZeneca and Merck drugs set to shake up treatment of liver cancer

Two late-stage studies published Wednesday in The Lancet show that Astra's Imfinzi and Merck's Keytruda delayed the progress of liver cancer when combined with other drugs and a local treatment

Merck India appoints Dhananjay Singh as MD of its Life Science unit

Over the years, Singh has taken on several leadership roles in commercial organisations such as Sigma-Aldrich and Merck India

DCGI approves MSD India's drug KEYTRUDA for breast cancer in adult patients

Renal cell carcinoma (RCC), the most common type of kidney cancer, predominantly affects men and has limited treatment options, often leaving patients at risk of recurrence

Excess vaccine-making capacity may get utilised in 3-5 years: Merck Life

Some 40-50 firms in India are getting into mRNA technology, says Aditya Sharma, senior executive of the German company

Merck's Covid medicine linked to virus mutation patterns, says study

Findings adds weight to earlier work by the same team of researchers that suggested that drug-induced mutations of Covid were spreading in some populations, although not in great numbers

Merck sues federal govt over plan to negotiate Medicare drug prices

Merck is suing the federal government over a plan to negotiate Medicare drug prices, calling the programme a sham equivalent to extortion. The drugmaker is seeking to halt the programme, which was laid out in the Inflation Reduction Act and is expected to save taxpayers billions of dollars in the coming years. Merck said in a complaint filed Tuesday that the programme does not involve genuine negotiation. Instead, it said the U.S. Department of Health and Human Services selects drugs to be included and then dictates the price, threatening drugmakers with a ruinous daily excise tax if they decline to agree. It is tantamount to extortion, the drugmaker said in the complaint, which was filed in the U.S. District Court for the District of Columbia. The drugmaker added that it expects its diabetes treatment Januvia to be part of the IRA's scheme starting later this year. Representatives of the federal agency did not immediately respond to requests for comment from The Associated Press

Innovator drugs maintain market hold even after patent expiry, shows data

Merck's anti-diabetic molecule sitagliptin retains 81% market share in value terms

Bayer launches novel heart failure drug Verquvo for Rs 127 a pill

In India there are between 8-10 million people with heart failure, making it one of the world's largest populations with the malady

Merck in advanced talks to buy Seagen in nearly $40-bn deal: Report

Seagen has several clinical-stage oncology candidates, as well as four approved drugs including breast cancer therapy Tukysa

Molnupiravir appears to work against Omicron as other variants: Study

The study was jointly conducted by a team of doctors at Fortis C-DOC, G.D Hospital and Diabetes Institute, Jawaharlal Nehru Medical College and Hospital, and the Diabetes Foundation

Drugmaker Merck has strong fourth quarter as Covid-19 treatment debuts

The blockbuster cancer treatment Keytruda pushed Merck past fourth-quarter expectations, and the drugmaker's COVID-19 treatment debuted with nearly $1 billion in sales. Sales for the Gardasil vaccine, which protects against cancer-causing human papilloma virus infections, jumped 50%, Merck said Thursday. Merck earned $3.75 billion in the final quarter of 2021 and sales jumping 24% to $13.52 billion. Adjusted earnings, which exclude items like interest expense, totalled $1.80 per share, far exceeding Wall Street's per-share projections of $1.53, according to a survey by the data firm FactSet. Merck sales also topped the quarterly revenue expectations of $13.16 billion from industry analysts. The drugmaker expects adjusted earnings of $7.12 to $7.27 per share on $56.1 billion to $57.6 billion in revenue. Wall Street has been projecting earnings of $7.30 per share on $56.71 billion in revenue. Shares of Merck & Co., based in Kenilworth, New Jersey, slipped 17 cents to $81.84 in ear

Anti-viral drug Molnupiravir has no observed safety concerns: MSD India

US drug firm defends its drug amid concerns over safety

Covid LIVE: Mumbai, Delhi again report sharp rise in daily new cases

2,510 new Covid cases reported in Mumbai on Wednesday, 82% higher than Tuesday, while Delhi reports 86% jump at 923 new infections

Two vaccines, Merck drug cleared for emergency use amid Omicron rise

150 mn doses of Corbevax, Covovax expected monthly from March

US nod for Covid-19 drug molnupiravir raises hope for Indian approval

Oral medication targets ribonucleic acid polymerase, a part of the virus that has not changed much after mutations in the Omicron variant.

USFDA panel votes in favour of first-of-a-kind Covid-19 pill from Merck

A Food and Drug Administration panel voted 13-10 that the drug's benefits outweigh its risks, including potential birth defects if used during pregnancy